BOSTON – Dyno Therapeutics hosted an ambitious event in Boston this week, the Genome Agency Technology Conference (GATC)*, striving to bring together a broad coalition of researchers and executives in cell and gene therapy, gene editing, drug discovery and AI as well as patients and advocates to forge new pathways of collaboration to expedite progress in delivering therapies to patients.
The one-day conference was the brainchild of Eric Kelsic, PhD, the founding CEO of Dyno, a biotech company co-founded by Harvard Medical School geneticist George Church, PhD, in 2018. Kelsic said the idea for GATC was hatched earlier this year, shortly before the American Society of Cell and Gene Therapy meeting and steadily expanded in scope.
The meeting hinges on the concept of genetic agency,…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
